Gilead Science任命Sanofi的Dietomar Berger为首席医务官,负责加强药物开发。 Gilead Sciences appoints Sanofi's Dietmar Berger as Chief Medical Officer to bolster drug development.

Gilead Science已任命来自萨诺菲的Dietmar Berger博士、MD博士、Dietmar Berger为新的首席医务官。 Gilead Sciences has appointed Dietmar Berger, MD, PhD, from Sanofi, as its new Chief Medical Officer. Berger将药物开发和医疗事务方面的丰富经验带给Gilead公司,该公司是一家主要的生物制药公司,重点开发创新药品。 Berger brings extensive experience in drug development and medical affairs to Gilead, a leading biopharmaceutical company focused on developing innovative medicines. 预计这一行动将加强Gilead的临床研究和开发工作。 The move is expected to strengthen Gilead's clinical research and development efforts.